Arcellx

Arcellx CapEx/OCF

Delisted

The CapEx to Operating Cash Flow Ratio of Arcellx (ACLX) as of Nov 21, 2026 is -1.11 %. In the previous year, CapEx to Operating Cash Flow Ratio was -16.09 % — a change of -93.12% (higher).

CapEx/OCF

-1.11 %

YoY

-93.12%

Last updated:

CapEx to Operating Cash Flow Ratio of Arcellx is 2025 -1.11 % . CapEx to Operating Cash Flow Ratio of Arcellx was 2024 -16.09 % . It decreases by -93.12% higher compared to the previous year.

The Arcellx CapEx/OCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/OCF
Date
CapEx/OCF
Jan 1, 2018
-6.98 USD
Jan 1, 2019
-20.41 USD
Jan 1, 2020
-3.10 USD
Jan 1, 2021
-10.66 USD
Jan 1, 2022
-2.29 USD
Jan 1, 2023
10.32 USD
Jan 1, 2024
-16.09 USD
Jan 1, 2025
-1.11 USD
The Arcellx CapEx/OCF history
YEARCapEx/OCFYoY
-1.11 %-93.12%
-16.09 %-255.91%
10.32 %-550.20%
-2.29 %-78.49%
-10.66 %+244.15%
-3.10 %-84.82%
-20.41 %+192.39%
-6.98 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Arcellx Stock analysis

What does Arcellx do? Arcellx, Inc develops innovative immunotherapies for cancer and incurable diseases, focusing on controllable cell therapies. The company's lead product CART-ddBCMA, a BCMA-targeting ddCAR therapy, is in a pivotal Phase II trial for relapsed or refractory multiple myeloma. Arcellx also advances two clinical-stage ARC-SparX programs: ACLX-001 for BCMA-targeting in multiple myeloma and ACLX-002 for CD123-targeting in acute myeloid leukemia and myelodysplastic syndrome. These therapies are developed using the company's D-Domain technology, with the goal of providing treatment options for patients with limited alternatives. Arcellx generates revenue through the development and clinical advancement of its cell therapy programs. The company's primary focus is on securing funding from strategic partnerships and clinical trial sponsorships to support its research and development activities. The key segments include patients with relapsed or refractory multiple myeloma, acute myeloid leukemia, and high-risk myelodysplastic syndrome, who are the target populations for its therapies. The company's lead program, CART-ddBCMA, is being evaluated in a pivotal Phase II trial, which is critical for advancing the therapy toward potential market approval. The firm's development pipeline includes CART-ddBCMA, ACLX-001, and ACLX-002, all leveraging the D-Domain technology for controllable cell therapies. Arcellx's business model centers on advancing these therapies through clinical trials to demonstrate efficacy and safety, with the ultimate goal of commercializing them for patients with unmet medical needs. The company's strategic partnerships and clinical trial sponsorships are essential for funding the progression of its programs from preclinical to clinical stages. Arcellx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Arcellx stock

CapEx to Operating Cash Flow Ratio of Arcellx is -1.11 % in 2025.

CapEx to Operating Cash Flow Ratio of Arcellx changed from -16.09 % to -1.11 %, representing a -93.12% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Operating Cash Flow Ratio Arcellx since 2006 – with annual values, charts, and detailed analysis.

The CapEx/OCF ratio shows what percentage of operating cash flow is reinvested in capital assets. Lower ratios indicate more free cash available for shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Operating Cash Flow Ratio's Arcellx with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Operating Cash Flow Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Operating Cash Flow Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Arcellx

All Key Metrics — Arcellx